Immunotherapy targeting the PD-1/PD-L1 axis has shown remarkable efficacy in different tumor types and has become the standard of care for the management of locally advanced and metastatic NSCLC (6–9). This evidence concerns the gene CD274 and non-small cell lung carcinoma.